Heron Neutron Medical announced two major milestones on March 10: the successful appeal of its F18 FBPA injection IND and its inclusion as a constituent in the MSCI Global Small Cap Index.

• Clinical Breakthrough: The Taiwan Food and Drug Administration (TFDA) has approved the re-examination for an academic human clinical trial of the F18 FBPA injection. This radiopharmaceutical tracer targets the amino acid transporter LAT1, which is highly expressed in tumor cells.
• Precision Medicine: Used in conjunction with PET/CT imaging, F18 FBPA allows for the assessment of tumor location and activity. This is critical for screening patients before Boron Neutron Capture Therapy (BNCT) to evaluate their uptake of boron-containing drugs, ensuring optimal treatment efficacy.
• Corporate Growth: Currently, no manufacturer worldwide holds a drug license for an F18 FBPA injection. Heron Neutron Medical aims to obtain its boron-neutron drug license by the end of 2025, with institutional analysts projecting significant earnings growth starting in 2027 as partner hospitals enter commercial operations. The MSCI index adjustment will take effect after the market closes on February 27.

Resource: 雙喜臨門！禾榮科F18 FBPA注射劑IND申覆過關，獲納MSCI小型指數成分股